| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5705631 | Ophthalmology | 2016 | 16 Pages |
Abstract
The OASIS trial demonstrates the long-term efficacy and safety of ocriplasmin, providing improved resolution of symptomatic VMA compared with previous phase 3 trials with no additional safety signals identified.
Keywords
FTMHffERGSD OCTLOCFcentral reading centerBCVAVMTADRinner segment/outer segmentVFQ-25ERMIS/OSFASERGVMAPpselectroretinogramOctbest-corrected visual acuityfull analysis setOptical coherence tomographyspectral domain optical coherence tomographyper protocol setfull-thickness macular holeadverse eventAdverse drug reactionepiretinal membraneconfidence intervallast observation carried forwardOasisvitreomacular adhesionCRCvitreomacular traction
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Pravin U. MD, Michael MD, Leonard MD, PhD, Petra MD, PhD, Annick PhD,